2022 Pediatric Cancer Research – Special Grant Opportunity
V Scholar or Translational or All-Star
2022 Request for Applications

PURPOSE OF AWARD: Due to exceptional fundraising levels in 2022, the V Foundation is offering an additional pediatric cancer research grant opportunity. This grant opportunity will be implemented through one of three grant mechanisms: V Scholar, Translational, or All-Star grant types. Award amounts will be significantly larger for each of these mechanisms and strict eligibility criteria for each are listed below.

SPECIAL FOCUS AREA: This request for applications is specifically for pediatric cancer research utilizing three different grant mechanisms.

V Scholar applicants can propose pediatric cancer research that is focused on laboratory research that increases our understanding of cancer biology or translational type research that improves cancer detection, prevention, treatment, and survivorship. Emphasis for this grant mechanism is on supporting exceptional early career investigators at the Assistant Professor stage to be better positioned to leverage large R01 or similar sustaining grants.

Translational grant applicants can propose pediatric cancer research that moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years from the end of the grant. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new pediatric clinical trial.

All Star grant applicants can propose any area of pediatric cancer research, as outlined in either example above. All-Star grant applicants must have previously received a V Foundation grant (V Scholar, Translational or Designated cancer research grant) to be eligible to apply for the All-Star grant.

Note: Research areas not included in this scope for any grant type are epidemiology, behavioral science, and health services research.

GRANT SPECIFICS:

V Scholar: $600,000, paid in 3 annual installments. No indirect costs allowed.

Translational: $800,000, paid in 4 annual installments. Indirect costs up to 10% allowed (not to exceed $80,000 within the award).

All Star: $1,000,000, paid in 5 annual installments. Indirect costs up to 10% allowed (not to exceed $100,000 within the award).
WHO MAY APPLY?

- Each invited institution may submit one nominee to apply for this pediatric RFA.
- The SOLE nominee may apply in either the V Scholar or Translational or the All-Star grant type.

INSTITUTION ELIGIBILITY:

Only research institutions that received this invitation may submit a nominee for consideration. Other affiliates of the institution that did not receive the email are not eligible to nominate an applicant.

APPLICANT ELIGIBILITY: Your nominee must be the lead Principal Investigator (PI) and must meet all of the following criteria by the nomination due date of August 22, 2022.

- For ALL applicant types:
  - Nominated by their Cancer Center Director or similar high ranking research official.
  - Employed at a non-profit research institution (e.g., 501c3, Section 170).
  - Must hold a tenure-track or tenured faculty position at their cancer research institution. Non-promotable adjunct, affiliated, temporary, part-time, or acting faculty positions are not eligible for Principal Investigator nomination.

- Specific For Translational and All-Star applicants: Must be either a US Citizen or have a legal permit (temporary or permanent) to work in the US. This requirement does not apply to invited Canadian institutions.

- Specific for V Scholar applicants:
  - Must be a US citizen or have permanent legal residency in the US. This requirement does not apply to invited Canadian institutions.
  - Must possess at least 2 years post-doctoral (MD or PhD) fellowship training. For MDs, a minimum of one year is acceptable if only one year is required for their specialty.
  - Clinical scientists are eligible if the research institution can demonstrate that it will fully support the research applicant (e.g., dedicated lab space, committed research time, start-up funds).
  - V Scholar applicants must have been appointed to their first full-time tenure track Assistant Professor position no more than 5 years prior to the nomination due date of August 22, 2022, and not yet been promoted to Associate Professor (for e.g., must be eligible to apply for PI status on an R01 at your institution).

Exclusions for V Scholar applicants:

- Must NOT have been a previous or current V Foundation V Scholar awardee.
- Must NOT have accepted or have received notification that you will be awarded an R01 or other large grant exceeding $250K per year in funding to your lab from public or private sources by this nomination due date of August 22, 2022. Internal/start-up institutional funds should not be included in the calculation.
- Must NOT have accepted or have received notification of aggregated funding exceeding $300K per year for more than 3 consecutive years by this nomination due date of August 22, 2022. Internal/start-up institutional funds should not be included in this aggregate calculation.

Specific for All-Star applicants:

- Must have previously received a V Foundation funded research award to be eligible to apply for this larger grant. The previous grant award is not required to be in the area of pediatrics and the two projects do not need to be linked.
Must have either a completed V Foundation grant or if grant is still open, must be in the final year of a previously funded V Foundation grant and in good standing with the V Foundation.

Must list previous V Foundation funding and a URL link to the previous grant on the V Foundation website within the support letter from the cancer center director/department head and on the nomination form.

NEXT STEPS:

Nomination Form:
- The single nominee from your institution may apply for one of the three program types.
- Select and complete the appropriate Nomination Form for your sole nominee, based on the pediatric program type (V Scholar, Translational or All-Star) for which your nominee will be applying.
- The nomination form must include the signature of the primary researcher and the Cancer Center Director (or similar high ranking research official) who is responsible for the nomination.
- Email the completed Nomination Form with all required accompanying documents in one email to nominations@v.org.
- The nominee will then be invited via email to complete the online application. Please allow at least 5 business days from the time of receipt for our team to process your nomination, verify preliminary eligibility and invite the nominee.

Recommendation Letter: Nominees will be asked to provide a Letter of Recommendation from the cancer center director or other senior official nominating the applicant with their nomination form and to upload a copy with their online application. This Letter of Recommendation should include:
- A description of the process used to identify your nominee
- Why you chose this nominee
- The institutional resources that will be available to the nominee
- The mentoring environment that will be available to the nominee (V Scholar only)
- If the nature of the research is bench to bedside with patient contact, describe how patient advocacy/communication will be incorporated into their training.
- Previous V Foundation funding and a URL link to the previous grant on the V Foundation website (All-Star only)

IMPORTANT DATES:
Nomination Due Date: by 5:00 PM Eastern Time on August 22, 2022
Application Due Date: by 5:00 PM Eastern Time on October 17, 2022
If you have questions about the nomination process, please contact the Research and Grants Team at Grants@v.org. We are delighted to extend this invitation and look forward to receiving your nomination.

Best Wishes,

Carole C. Wegner, PhD
Senior Vice President, Research and Grants Administration
the V Foundation for Cancer Research
VICTORY OVER CANCER